<p>加拿大温哥华，2026 年 5 月 18 日（GLOBE NEWSWIRE）——Clearmind Medicine Inc.（纳斯达克：CMND）（“Clearmind” 或 “公司”）是一家临床阶段的生物技术公司，专注于发现和开发新型非致幻的第二代神经塑性药物，以解决主要的未充分治疗的健康问题。今天，公司宣布与耶路撒冷希伯来大学的 Yissum 研究发展公司签署了一项新的研究协议。该协议将资助一项全面的临床前研究，评估 MEAI（CMND-100）的代谢疗效，包括与 tirzepatide 治疗结合使用及作为饮食诱导肥胖（“DIO”）小鼠的维持治疗。该研究将由耶路撒冷希伯来大学药物研究所药学院的 Joseph（Yossi）Tam 教授及其团队进行。</p>
<p>基于胰高血糖素样肽的疗法和 tirzepatide 的全球市场已经发展成为一个庞大的产业，预计在 2025 年价值约为 500 亿至 660 亿美元，并预计到 2033 年将达到 1700 亿至 1850 亿美元。这些疗法显著推动了肥胖和 2 型糖尿病的治疗，带来了显著的体重减轻和心代谢改善。尽管取得了显著成功，GLP-1 和双重 GLP-1/GIP 受体激动剂主要通过抑制食欲和减少能量摄入来发挥作用。一个主要的临床挑战仍然存在：在停药后，通常会出现显著的体重反弹——往往在一年内恢复失去体重的 25% 或更多，同时代谢益处也会部分逆转。这突显了迫切需要补充或维持策略，以增强治疗的持久性，帮助保持瘦体重，并积极提高能量消耗。</p>
<p>在与耶路撒冷希伯来大学 Yossi Tam 教授实验室的先前合作中，MEAI 在 DIO 小鼠中显示出约 15% 至 20% 的体重减轻，主要通过增加能量消耗和脂肪利用，同时保持瘦体重并改善葡萄糖稳态和肝脂肪变性，Clearmind 现在正在推进 MEAI 与当今领先的胰高血糖素疗法的组合和序列策略。</p>
<p>新的为期 12 个月的研究，题为 “评估 MEAI 与 tirzepatide 联合和序列使用在饮食诱导肥胖小鼠中的代谢疗效”，将研究：MEAI 与 tirzepatide 同时给药时的附加或协同效应，以及 MEAI 作为维持治疗以减轻停用 tirzepatide 后的体重反弹和保持代谢益处的潜力，涵盖多个剂量。</p>
<p>“MEAI 旨在提供一种差异化的机制，可能补充胰高血糖素疗法，” Clearmind Medicine 首席执行官 Adi Zuloff-Shani 博士表示。“虽然这些药物在减少食物摄入方面表现出色，但我们之前的临床前数据表明，MEAI 显著增强了能量消耗。我们相信，这种组合和维持的方法有潜力为患者提供更强大、持久和临床上有意义的结果。”</p>
<p><strong>关于 Clearmind Medicine Inc.</strong></p>
<p>Clearmind 是一家临床阶段的神经塑性药物生物技术公司，专注于发现和开发非致幻的第二代神经塑性药物，以解决广泛且未得到充分服务的健康问题，包括酒精使用障碍。其主要目标是研究和开发基于迷幻药的化合物，并尝试将其商业化为受监管的药物、食品或补充剂。</p>
<p>公司的知识产权组合目前包括十九个专利系列，其中包括 31 项已授予的专利。公司打算在必要时为其化合物申请额外的专利，并将保持机会主义，以获取更多知识产权以扩展其组合。</p>
<p>Clearmind 的股票在纳斯达克上市，股票代码为 “CMND”。</p>
<p>欲了解更多信息，请访问：https://www.clearmindmedicine.com 或联系：</p>
<p>投资者关系</p>
<p>invest@clearmindmedicine.com</p>
<p>www.Clearmindmedicine.com</p>
<p><strong>前瞻性声明：</strong></p>
<p>本新闻稿包含《私人证券诉讼改革法案》和其他证券法意义上的 “前瞻性声明”。诸如 “预计”、“预期”、“打算”、“计划”、“相信”、“寻求”、“估计” 等词语或类似表达及其变体旨在识别前瞻性声明。例如，当公司讨论全球基于胰高血糖素样肽疗法市场的预期增长、Clearmind 如何将 MEAI 推进到与当前领先的胰高血糖素样肽疗法的组合和序列策略时，MEAI 被设计为提供一种可能补充胰高血糖素样肽疗法的差异化机制，并且公司相信 MEAI 与胰高血糖素样肽疗法的组合和维持方法有潜力为患者提供更强大、持久和具有临床意义的结果时，便使用了前瞻性声明。前瞻性声明不是历史事实，而是基于管理层当前的期望、信念和预测，其中许多本质上具有不确定性。这些期望、信念和预测是以善意表达的。然而，无法保证管理层的期望、信念和预测将会实现，实际结果可能与前瞻性声明中所表达或指示的内容有实质性差异。前瞻性声明受到风险和不确定性的影响，这可能导致实际表现或结果与前瞻性声明中所表达的内容有实质性差异。有关影响公司的风险和不确定性的更详细描述，请参考公司不时向证券交易委员会（“SEC”）提交的报告，包括但不限于公司截至 2025 年 10 月 31 日的财政年度的 20-F 表格年报中详细列出的风险及随后向 SEC 提交的文件。前瞻性声明仅在声明发布之日有效。公司不承担更新前瞻性声明以反映实际结果、后续事件或情况、假设变化或影响前瞻性信息的其他因素变化的义务，除非适用的证券法要求。如果公司更新一项或多项前瞻性声明，不应推断公司将就此或其他前瞻性声明进行额外更新。提供的参考和链接仅为方便，网站上包含的信息不被纳入本新闻稿的引用。Clearmind 对第三方网站的内容不承担责任。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeU1qRXdNU00zTmpBNE5URTJJelV3TURBNE5qa3pOQT09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeU1qRXdNU00zTmpBNE5URTJJelV3TURBNE5qa3pOQT09"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YjljNzQyZTItYWUwNy00MmY0LWI5MWItNGZlZDNlMTVjYzEzLTUwMDA4NjkzNC0yMDI2LTA1LTE4LWVu/tiny/Clearmind-Medicine-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YjljNzQyZTItYWUwNy00MmY0LWI5MWItNGZlZDNlMTVjYzEzLTUwMDA4NjkzNC0yMDI2LTA1LTE4LWVu/tiny/Clearmind-Medicine-Inc-.png"/></p>

CMND

礼来

<p>Clearmind Medicine Inc. 已与 Yissum Research Development Company 签署了一项研究协议，旨在研究 MEAI 与 tirzepatide 联合使用在饮食诱导肥胖小鼠中的代谢疗效。为期 12 个月的研究旨在评估 MEAI 作为维持治疗的潜力，以防止在 tirzepatide 治疗后体重反弹。Clearmind 的首席执行官 Adi Zuloff-Shani 博士认为，这种组合可能增强治疗的持久性并改善患者的治疗效果</p>

<p>Vancouver, Canada, May 18, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the &#34;Company&#34;), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second-generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the signing of a new research agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. The agreement will fund a comprehensive preclinical study evaluating the metabolic efficacy of MEAI (CMND-100), both in combination with and as a maintenance therapy following tirzepatide treatment in diet-induced obese (&#34;DIO&#34;) mice. The research will be conducted by Professor Joseph (Yossi) Tam and his team at the Obesity and Metabolism Laboratory at the Institute for Drug Research, School of Pharmacy, Hebrew University of Jerusalem.</p>
<div class="lb-trans"><p>加拿大温哥华，2026 年 5 月 18 日（GLOBE NEWSWIRE）——Clearmind Medicine Inc.（纳斯达克：CMND）（“Clearmind” 或 “公司”）是一家临床阶段的生物技术公司，专注于发现和开发新型非致幻的第二代神经塑性药物，以解决主要的未充分治疗的健康问题。今天，公司宣布与耶路撒冷希伯来大学的 Yissum 研究发展公司签署了一项新的研究协议。该协议将资助一项全面的临床前研究，评估 MEAI（CMND-100）的代谢疗效，包括与 tirzepatide 治疗结合使用及作为饮食诱导肥胖（“DIO”）小鼠的维持治疗。该研究将由耶路撒冷希伯来大学药物研究所药学院的 Joseph（Yossi）Tam 教授及其团队进行。</p>
</div><p>The global market for incretin-based therapies and tirzepatide has grown into a massive industry valued at approximately $50–66 billion in 2025, and is projected to reach $170–185 billion by 2033. These therapies have significantly advanced the treatment of obesity and type 2 diabetes, delivering substantial weight loss and cardiometabolic improvements. Despite their remarkable success, GLP-1 and dual GLP-1/GIP receptor agonists primarily work by suppressing appetite and reducing energy intake. A major clinical challenge remains: substantial weight regain- often 25% or more of the lost weight within one year, along with partial reversal of metabolic benefits, frequently occurs upon discontinuation. This underscores the urgent need for complementary or maintenance strategies that can enhance treatment durability, help preserve lean muscle mass, and actively boost energy expenditure.</p>
<div class="lb-trans"><p>基于胰高血糖素样肽的疗法和 tirzepatide 的全球市场已经发展成为一个庞大的产业，预计在 2025 年价值约为 500 亿至 660 亿美元，并预计到 2033 年将达到 1700 亿至 1850 亿美元。这些疗法显著推动了肥胖和 2 型糖尿病的治疗，带来了显著的体重减轻和心代谢改善。尽管取得了显著成功，GLP-1 和双重 GLP-1/GIP 受体激动剂主要通过抑制食欲和减少能量摄入来发挥作用。一个主要的临床挑战仍然存在：在停药后，通常会出现显著的体重反弹——往往在一年内恢复失去体重的 25% 或更多，同时代谢益处也会部分逆转。这突显了迫切需要补充或维持策略，以增强治疗的持久性，帮助保持瘦体重，并积极提高能量消耗。</p>
</div><p>Building on positive results from its prior collaboration with Professor Yossi Tam’s laboratory at the Hebrew University, where MEAI demonstrated approximately 15–20% body weight reduction in DIO mice, primarily through increased energy expenditure and fat utilization while preserving lean mass and improving glucose homeostasis and hepatic steatosis, Clearmind is now advancing MEAI into combination and sequencing strategies with today’s leading incretin therapy.</p>
<div class="lb-trans"><p>在与耶路撒冷希伯来大学 Yossi Tam 教授实验室的先前合作中，MEAI 在 DIO 小鼠中显示出约 15% 至 20% 的体重减轻，主要通过增加能量消耗和脂肪利用，同时保持瘦体重并改善葡萄糖稳态和肝脂肪变性，Clearmind 现在正在推进 MEAI 与当今领先的胰高血糖素疗法的组合和序列策略。</p>
</div><p>The new 12-month study, titled “Assessing the Metabolic Efficacy of MEAI in Combination and Sequencing with Tirzepatide in Diet-Induced Obese Mice,” will examine: Additive or synergistic effects when MEAI is administered concomitantly with tirzepatide and the potential of MEAI as a maintenance therapy to attenuate post-tirzepatide weight regain and preserve metabolic benefits across multiple doses.</p>
<div class="lb-trans"><p>新的为期 12 个月的研究，题为 “评估 MEAI 与 tirzepatide 联合和序列使用在饮食诱导肥胖小鼠中的代谢疗效”，将研究：MEAI 与 tirzepatide 同时给药时的附加或协同效应，以及 MEAI 作为维持治疗以减轻停用 tirzepatide 后的体重反弹和保持代谢益处的潜力，涵盖多个剂量。</p>
</div><p>“MEAI is designed to offer a differentiated mechanism that potentially complements incretin therapies,” said Dr. Adi Zuloff-Shani, Ph.D., Chief Executive Officer of Clearmind Medicine. “While those drugs excel at reducing food intake, our previous preclinical data show MEAI significantly enhances energy expenditure. We believe that this combination and maintenance approach has potential to deliver more robust, durable, and clinically meaningful outcomes for patients.”</p>
<div class="lb-trans"><p>“MEAI 旨在提供一种差异化的机制，可能补充胰高血糖素疗法，” Clearmind Medicine 首席执行官 Adi Zuloff-Shani 博士表示。“虽然这些药物在减少食物摄入方面表现出色，但我们之前的临床前数据表明，MEAI 显著增强了能量消耗。我们相信，这种组合和维持的方法有潜力为患者提供更强大、持久和临床上有意义的结果。”</p>
</div><p><strong>About Clearmind Medicine Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Clearmind Medicine Inc.</strong></p>
</div><p>Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.</p>
<div class="lb-trans"><p>Clearmind 是一家临床阶段的神经塑性药物生物技术公司，专注于发现和开发非致幻的第二代神经塑性药物，以解决广泛且未得到充分服务的健康问题，包括酒精使用障碍。其主要目标是研究和开发基于迷幻药的化合物，并尝试将其商业化为受监管的药物、食品或补充剂。</p>
</div><p>The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.</p>
<div class="lb-trans"><p>公司的知识产权组合目前包括十九个专利系列，其中包括 31 项已授予的专利。公司打算在必要时为其化合物申请额外的专利，并将保持机会主义，以获取更多知识产权以扩展其组合。</p>
</div><p>Shares of Clearmind are listed for trading on Nasdaq under the symbol &#34;CMND.&#34;</p>
<div class="lb-trans"><p>Clearmind 的股票在纳斯达克上市，股票代码为 “CMND”。</p>
</div><p>For further information, visit: https://www.clearmindmedicine.com or contact:</p>
<div class="lb-trans"><p>欲了解更多信息，请访问：https://www.clearmindmedicine.com 或联系：</p>
</div><p>Investor Relations</p>
<div class="lb-trans"><p>投资者关系</p>
</div><p>invest@clearmindmedicine.com</p>
<div class="lb-trans"><p>invest@clearmindmedicine.com</p>
</div><p>www.Clearmindmedicine.com</p>
<div class="lb-trans"><p>www.Clearmindmedicine.com</p>
</div><p><strong>Forward-Looking Statements:</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明：</strong></p>
</div><p>This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the expected growth of the global market for incretin-based therapies, how Clearmind is advancing MEAI into combination and sequencing strategies with today’s leading incretin therapy, how MEAI is designed to offer a differentiated mechanism that potentially complements incretin therapies and its belief that the combination and maintenance approach of MEAI and incretin therapies has potential to deliver more robust, durable, and clinically meaningful outcomes for patients. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.</p>
<div class="lb-trans"><p>本新闻稿包含《私人证券诉讼改革法案》和其他证券法意义上的 “前瞻性声明”。诸如 “预计”、“预期”、“打算”、“计划”、“相信”、“寻求”、“估计” 等词语或类似表达及其变体旨在识别前瞻性声明。例如，当公司讨论全球基于胰高血糖素样肽疗法市场的预期增长、Clearmind 如何将 MEAI 推进到与当前领先的胰高血糖素样肽疗法的组合和序列策略时，MEAI 被设计为提供一种可能补充胰高血糖素样肽疗法的差异化机制，并且公司相信 MEAI 与胰高血糖素样肽疗法的组合和维持方法有潜力为患者提供更强大、持久和具有临床意义的结果时，便使用了前瞻性声明。前瞻性声明不是历史事实，而是基于管理层当前的期望、信念和预测，其中许多本质上具有不确定性。这些期望、信念和预测是以善意表达的。然而，无法保证管理层的期望、信念和预测将会实现，实际结果可能与前瞻性声明中所表达或指示的内容有实质性差异。前瞻性声明受到风险和不确定性的影响，这可能导致实际表现或结果与前瞻性声明中所表达的内容有实质性差异。有关影响公司的风险和不确定性的更详细描述，请参考公司不时向证券交易委员会（“SEC”）提交的报告，包括但不限于公司截至 2025 年 10 月 31 日的财政年度的 20-F 表格年报中详细列出的风险及随后向 SEC 提交的文件。前瞻性声明仅在声明发布之日有效。公司不承担更新前瞻性声明以反映实际结果、后续事件或情况、假设变化或影响前瞻性信息的其他因素变化的义务，除非适用的证券法要求。如果公司更新一项或多项前瞻性声明，不应推断公司将就此或其他前瞻性声明进行额外更新。提供的参考和链接仅为方便，网站上包含的信息不被纳入本新闻稿的引用。Clearmind 对第三方网站的内容不承担责任。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeU1qRXdNU00zTmpBNE5URTJJelV3TURBNE5qa3pOQT09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTcyMjEwMSM3NjA4NTE2IzUwMDA4NjkzNA=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YjljNzQyZTItYWUwNy00MmY0LWI5MWItNGZlZDNlMTVjYzEzLTUwMDA4NjkzNC0yMDI2LTA1LTE4LWVu/tiny/Clearmind-Medicine-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/YjljNzQyZTItYWUwNy00MmY0LWI5MWItNGZlZDNlMTVjYzEzLTUwMDA4NjkzNC0yMDI2LTA1LTE4LWVu/tiny/Clearmind-Medicine-Inc-.png"/></p>

Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications | CMND Stock News

Clearmind Medicine 签署协议，研究 MEAI 与 Tirzepatide 的组合及排序，以对抗重磅 GLP-1 药物 | CMND 股票新闻